Form 4: Coya Therapeutics Grants Executive Chairman Stock Options

Coya Therapeutics, Inc. has granted its Executive Chairman, Howard Berman, 15,257 stock options with an exercise price of $4.73, vesting over 36 months.

Summary

• Howard Berman, Executive Chairman and Director of Coya Therapeutics, Inc. (COYA), was granted 15,257 stock options.
• The options have an exercise price of $4.73 per share.
• The grant date for these options was January 22, 2026.
• The options will vest in monthly installments over 36 months, contingent on continuous service.
• The options expire on January 22, 2036.
• In the event of a change in control of Coya Therapeutics, the options will immediately vest and become exercisable under the company's 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (stock option grant) which is generally positive for aligning management incentives but has a minor dilutive potential. It does not contain significant news to dramatically shift sentiment.

Positives

• Aligns management's interests (Executive Chairman Howard Berman) with shareholder value through equity incentives.
• The vesting schedule encourages long-term commitment and continuous service from a key executive.
• The grant is consistent with the company's 2021 Equity Incentive Plan, indicating structured compensation practices.

Negatives

• Potential for future dilution if the options are exercised, increasing the number of outstanding shares.

Future Outlook

The stock options granted to Howard Berman are subject to a 36-month vesting schedule, contingent on his continuous service, indicating an expectation of his ongoing role and contribution to the company's future performance. The immediate vesting upon a change in control provides an incentive structure related to potential future corporate events.

Industry Context

This is a routine executive compensation event common across all industries, particularly in biotechnology where long-term incentives are crucial for retaining key talent and aligning their interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to executive leadership is a standard practice in publicly traded companies, especially in the biotech sector, to incentivize performance and retention.
• A 3-year vesting schedule (36 months) is a common industry standard for equity awards, balancing immediate incentive with long-term commitment.
• The inclusion of a change-in-control clause is also standard practice, providing protection and incentive for executives during potential M&A activities, similar to practices seen in companies like Amgen or Gilead Sciences.

Corporate Governance

Related Party Transactions

• The grant of stock options to Howard Berman, an Executive Chairman and Director, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefits from aligned management incentives for long-term value creation.
• Employees: May signal stability in executive leadership and adherence to established compensation plans.

Next Steps

• Howard Berman's continued service to Coya Therapeutics over the next 36 months for the options to fully vest.
• Potential exercise of options by Howard Berman upon vesting and favorable stock price movement.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event, specifically the grant of stock options to the Executive Chairman. While it aligns management incentives with shareholder value, it does not provide new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions, as this specific filing is not a catalyst for a 'buy' or 'sell' decision.

Keywords

Coya Therapeutics, COYA, Howard Berman, Stock Options, SEC Form 4, Executive Compensation, Equity Incentive Plan, Director, Executive Chairman, Beneficial Ownership